N. Jones

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions

Jin Y. Jin, Yuan Chen, L. Chinn, 2020, CPT: pharmacometrics & systems pharmacology.

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

J. Galanter, D. Isenberg, L. Chinn, 2021, Arthritis & rheumatology.

Pediatric Dose Selection and Utility of PBPK in Determining Dose

L. Musib, N. Jones, I. Templeton, 2018, The AAPS Journal.